Key TakeawaysPfizer shares rose as the company said it would be moving forward with studies of a once-a-day oral weight-loss pill after testing its modified release formulation.The pill has the same GLP-1 receptor agonists used in the injectable obesity treatments from Novo Nordisk and Eli Lilly.Pfizer reported the drug was successful when given twice a day, but caused adverse side effects. Shares of Pfizer (PFE) advanced as the drug maker announced that it was moving forward with research into a potential ...